Skip to main content

View full-text article in PMC

. 2020 May 15;59(12):3759–3766. doi: 10.1093/rheumatology/keaa198

Table 2.

Characteristics of the validation set with RA cases defined by chart review (n = 200)

	RA cases, n = 75	Controls (possible + no RA), n = 125	P-value
Age (mean (s.d.))	65.45 (16.10)	66.44 (17.40)	0.690
Female (n, %)	59 (78.7)	89 (71.2)	0.318
Seropositive^a (n, %)	20 (74.1)	5 (41.7)	0.113
Methotrexate (n, %)	37 (49.3)	13 (10.4)	<0.001
Anti-TNF (n, %)	21 (28.0)	8 (6.4)	<0.001

^a

% computed using available data. Anti-CCP: anti-cyclic citrullinated peptide; Anti-TNF: anti-tumour necrosis factor agents.